Targeted anti-IL-1β platelet microparticles for cardiac detoxing and repair.

Journal Article (Journal Article)

An acute myocardial infarction (AMI) induces a sterile inflammatory response that facilitates further heart injury and promotes adverse cardiac remodeling. Interleukin-1β (IL-1β) plays a central role in the sterile inflammatory response that results from AMI. Thus, IL-1β blockage is a promising strategy for treatment of AMI. However, conventional IL-1β blockers lack targeting specificity. This increases the risk of serious side effects. To address this problem herein, we fabricated platelet microparticles (PMs) armed with anti-IL-1β antibodies to neutralize IL-1β after AMI and to prevent adverse cardiac remodeling. Our results indicate that the infarct-targeting PMs could bind to the injured heart, increasing the number of anti-IL-1β antibodies therein. The anti-IL-1β platelet PMs (IL1-PMs) protect the cardiomyocytes from apoptosis by neutralizing IL-1β and decreasing IL-1β-driven caspase-3 activity. Our findings indicate that IL1-PM is a promising cardiac detoxification agent that removes cytotoxic IL-1β during AMI and induces therapeutic cardiac repair.

Full Text

Duke Authors

Cited Authors

  • Li, Z; Hu, S; Huang, K; Su, T; Cores, J; Cheng, K

Published Date

  • February 2020

Published In

Volume / Issue

  • 6 / 6

Start / End Page

  • eaay0589 -

PubMed ID

  • 32076644

Pubmed Central ID

  • PMC7002120

Electronic International Standard Serial Number (EISSN)

  • 2375-2548

Digital Object Identifier (DOI)

  • 10.1126/sciadv.aay0589


  • eng

Conference Location

  • United States